RxSight (RXST) Stock: Buy, Sell, or Hold?
RXST - RxSight, Inc. Common Stock
$4.90
0.02 (0.41%)
▲
5d:
+8.41%
30d:
-0.61%
90d:
-8.75%
BUY
MODERATE Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 04, 2026
12d
Get Alerted When RXST Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RXST shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RXST shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RXST is currently trading at $4.90, which is considered fair relative to its 30-day fair value range of $4.54 to $5.24.
Technical Outlook: Technically, RXST is showing sideways momentum. The price is approaching resistance at $5.04. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: RXST scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.57 (+54.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RXST is showing sideways momentum. The price is approaching resistance at $5.04. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: RXST scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.57 (+54.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$4.54 -
$5.24
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (63/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 54.5% below Wall St target ($7.57)
- BULLISH: Bottoming setup score 63/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$4.54 -
$5.24
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.49
(9.9%)
Support & Resistance Levels
Support Level
$4.40
Resistance Level
$5.04
Current Trend
Sideways
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.17
Wall Street Target
$7.57
(+54.5%)
Revenue Growth (YoY)
0.3%
Profit Margin
-36.8%
Share & Embed Analysis
Last updated: October 22, 2026 7:05 AM ET
Data refreshes hourly during market hours. Next update: 8:05 AM
Data refreshes hourly during market hours. Next update: 8:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RXST showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
29 analysts |
$96 | 50 HOLD |
|
EW
Edwards Lifesciences Corp |
STRONG BUY
29 analysts |
$102 | 59 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
28 analysts |
$121 | 53 HOLD |
|
SYK
Stryker Corporation |
STRONG BUY
29 analysts |
$363 | 37 SELL |
|
CATX
Perspective Therapeutics… |
STRONG BUY
14 analysts |
$12 | 60 HOLD |
